- $877.15m
- $371.52m
- $67.48m
Brief: Kura Oncology And Kyowa Kirin Announce First Patient Dosed In Pivotal Phase 3 Komet-017 Trial
Kura Oncology Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Kura Oncology Q2 Collaboration Revenue USD 15.288 Million
Brief: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule
Brief: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data
U.S. STOCKS ON THE MOVE-Natgas companies, UnitedHealth, Cactus
U.S. STOCKS ON THE MOVE-Lyra Therapeutics, Church & Dwight, Applied Digital
U.S. STOCKS ON THE MOVE-Xilio Therapeutics, Red Rock Resorts, Kymera
U.S. STOCKS ON THE MOVE-Moderna, Blueprint Medicines, Boeing
Kura Oncology gains as FDA accepts marketing application for blood cancer drug
Kura Oncology Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Kura Oncology Q1 Operating Expenses USD 78.808 Million
Brief: Kura Oncology Announces First Patients Dosed In Phase 1 Combination Trial Of Ziftomenib For The Treatment Of Advanced Gist
Brief: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting
Kura Oncology Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Kura Oncology Q4 Operating Expenses USD 76.338 Million
Brief: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)